Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

kidney disease

This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

It’s the third time AZ has taken up an option on an Ionis drug under a 2015 alliance in the area of cardiovascular, metabolic and kidney disease, after earlier deals ... for cardiovascular drug AZD8233 and kidney disease candidate AZD2373.

Latest news

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take certain heart failure (HF) medicines that increase potassium levels in the blood.

  • AZ adds another Ionis drug in $330m kidney disease deal AZ adds another Ionis drug in $330m kidney disease deal

    AZ adds another Ionis drug in $330m kidney disease deal. The candidate targets a genetically associated form of the condition. ... AstraZeneca has signed another licensing deal with antisense specialist Ionis, this time paying $30m upfront and $300m in

  • After some big setbacks, Sanofi talks up its R&D portfolio After some big setbacks, Sanofi talks up its R&D portfolio

    Sanofi is highlighting half a dozen phase IIII programmes in the update, including dupilumab as a treatment for chronic obstructive pulmonary disease (COPD), oral GCS inhibitor venglustat for polycystic kidney disease,

  • Motif Bio preps US filing after antibiotic clears phase III Motif Bio preps US filing after antibiotic clears phase III

    Aside from its novel mechanism, iclaprim also appears to be free of the kidney-damaging toxicity that can be seen with vancomycin and means that patients on the drug need to ... be a candidate for around a quarter of the 3.6 million people who develop

  • J&J seeks US OK to add CV claim to Invokana label J&J seeks US OK to add CV claim to Invokana label

    Adults with type 2 diabetes are four times more likely to develop cardiovascular disease, and this is the leading cause of death in these patients. ... chronic kidney disease patients both with and without diabetes.

More from news
Approximately 18 fully matching, plus 128 partially matching documents found.

Latest Intelligence

  • The invisible army The invisible army

    Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease. ... inflammatory bowel disease and multiple sclerosis.

  • Business as usual Business as usual

    He also cautioned delegates over 'dual use', describing a situation where ferric citrate was promoted at a kidney disease symposium. ... It was described as being FDA-approved - which it is, but not for the treatment of kidney disease.

  • Deal Watch February 2016 Deal Watch February 2016

    The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases. ... licence. 105. †† Genexine/ Shanghai Chemo

  • Deal Watch December 2015 Deal Watch December 2015

    Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 397. Akebia (US). Mitsubishi. Collaboration, licence. Vadadustat for treatment of anaemia in chronic kidney disease.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Making good practice common practice in rare disease

    However, fatigue scores can’ t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia